Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 May 1;140(5):1004-1011.
doi: 10.1213/ANE.0000000000007188.

Risk of Acute Complications with Rocuronium versus Cisatracurium in Patients with Chronic Kidney Disease: A Propensity-Matched Study

Nikolas A Georgakis  1 , Sterling J DeShazo  1 , Jonathon I Gomez  1 , Michael P Kinsky  2 , Daniel Arango  2
Affiliations
Comparative Study

Risk of Acute Complications with Rocuronium versus Cisatracurium in Patients with Chronic Kidney Disease: A Propensity-Matched Study

Nikolas A Georgakis et al. Anesth Analg. .

Abstract

Background: Neuromuscular blocking agents (NMBAs) play an integral role in modern anesthesia by facilitating endotracheal tube placement, assisting with mechanical ventilation, and creating optimal surgical conditions. However, NMBAs can have deleterious side effects. The purpose of this study was to retrospectively analyze acute complications of 2 pharmacodynamically similar but pharmacokinetically different NMBAs and their respective reversal agents.

Methods: The global research network database, TriNetX, was used to evaluate deidentified patient information from 63 health care organizations. Cohort A was defined as patients aged 18 to 80 years who had chronic kidney disease (CKD) and were administered rocuronium with sugammadex. Cohort B was defined as patients aged 18 to 80 years who had CKD and were administered cisatracurium with neostigmine. Cohorts were propensity matched for age at event, ethnicity, race, sex, and relevant confounding pathologies. All outcomes besides mortality were analyzed from the same day to 1 week after administration of the indexed drug. Mortality was analyzed from the same day to thirty days after administration of the indexed drug.

Results: A total of 95,740 patients with CKD-administered rocuronium with sugammadex were matched with 10,708 patients with CKD-administered cisatracurium with neostigmine. Patients administered rocuronium with sugammadex had a significantly higher associated risk of respiratory failure (risk ratios [RR], 1.98, confidence interval [CI], 1.71-2.29, P < .0001), acute respiratory distress (RR, 2.70, CI, 1.31-5.58, P = .0052), hypertensive crisis (RR, 1.85, CI, 1.37-2.49, P < .0001), heart failure (RR, 1.14, CI, 1.06-1.23, P = .0004), pleural effusion (RR, 1.30, CI, 1.14-1.49, P < .0001), and 30-day mortality (RR, 1.31, CI, 1.10-1.56, P = .0021).

Conclusions: From 2003 to 2023, patients who were administered rocuronium plus sugammadex were at a significantly higher risk for acute cardiovascular and pulmonary complications when compared to patients who were administered cisatracurium plus neostigmine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest, Funding: Please see DISCLOSURES at the end of this article.

References

    1. Cook D, Simons DJ. Neuromuscular blockade. November 13, 2023. Accessed February 7, 2024. https://pubmed.ncbi.nlm.nih.gov/30855885/ .
    1. Flood P. The importance of myorelaxants in anesthesia. Curr Opin Pharmacol. 2005;5:322–327.
    1. Hager HH, Burns B. Succinylcholine chloride. February 20, 2023. Accessed February 15, 2024. https://pubmed.ncbi.nlm.nih.gov/29763160/ .
    1. Alvarellos ML, McDonagh EM, Patel S, McLeod HL, Altman RB, Klein TE. PharmGKB summary. Pharmacogenet Genomics. 2015;25:622–630.
    1. Larijani GE, Gratz I, Silverberg M, Jacobi AG. Clinical pharmacology of the neuromuscular blocking agents. DICP. 1991;25:54–64.

Publication types

MeSH terms